Alphatec Holdings, Inc. (NASDAQ:ATEC) EVP Sells $365,317.56 in Stock

Alphatec Holdings, Inc. (NASDAQ:ATEC) EVP David Sponsel sold 33,732 shares of the business’s stock in a transaction dated Thursday, March 6th. The shares were sold at an average price of $10.83, for a total transaction of $365,317.56. Following the completion of the transaction, the executive vice president now owns 668,977 shares in the company, valued at approximately $7,245,020.91. This trade represents a 4.80 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

David Sponsel also recently made the following trade(s):

• On Monday, February 24th, David Sponsel sold 12,946 shares of Alphatec stock. The shares were sold at an average price of $10.73, for a total transaction of $138,910.58.
• On Monday, February 3rd, David Sponsel sold 36,256 shares of Alphatec stock. The stock was sold at an average price of $11.42, for a total transaction of $414,043.52.
• On Monday, January 13th, David Sponsel sold 58,283 shares of Alphatec stock. The stock was sold at an average price of $10.71, for a total transaction of $624,210.93.
• On Friday, January 10th, David Sponsel sold 238 shares of Alphatec stock. The stock was sold at an average price of $10.00, for a total transaction of $2,380.00.

Alphatec Stock Down 3.9 %

Shares of NASDAQ ATEC opened at $9.56 on Thursday. The stock has a market cap of $1.38 billion, a P/E ratio of -7.47 and a beta of 1.39. The firm has a 50 day moving average price of $10.94 and a 200 day moving average price of $8.69. The company has a debt-to-equity ratio of 30.21, a quick ratio of 1.15 and a current ratio of 2.32. Alphatec Holdings, Inc. has a 52-week low of $4.88 and a 52-week high of $14.88.

Alphatec (NASDAQ:ATEC) last issued its quarterly earnings data on Wednesday, February 26th. The medical technology company reported ($0.23) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.04). The firm had revenue of $176.79 million for the quarter, compared to analyst estimates of $172.74 million. Alphatec had a negative net margin of 31.06% and a negative return on equity of 541.39%. Analysts expect that Alphatec Holdings, Inc. will post -1.08 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on the stock. StockNews.com raised shares of Alphatec from a “sell” rating to a “hold” rating in a research note on Friday, February 28th. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 target price on shares of Alphatec in a research note on Tuesday, January 14th. Barclays boosted their price target on shares of Alphatec from $20.00 to $21.00 and gave the stock an “overweight” rating in a research note on Wednesday, January 22nd. Needham & Company LLC reissued a “buy” rating and set a $16.00 price target on shares of Alphatec in a research note on Thursday, February 27th. Finally, Piper Sandler boosted their price target on shares of Alphatec from $12.00 to $13.00 and gave the stock an “overweight” rating in a research note on Thursday, February 27th. Two investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat.com, Alphatec currently has a consensus rating of “Moderate Buy” and a consensus price target of $17.67.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Comerica Bank boosted its holdings in shares of Alphatec by 66.8% in the fourth quarter. Comerica Bank now owns 3,116 shares of the medical technology company’s stock valued at $29,000 after buying an additional 1,248 shares during the period. R Squared Ltd acquired a new position in shares of Alphatec in the fourth quarter valued at approximately $29,000. Nisa Investment Advisors LLC boosted its holdings in shares of Alphatec by 973.3% in the fourth quarter. Nisa Investment Advisors LLC now owns 4,669 shares of the medical technology company’s stock valued at $43,000 after buying an additional 4,234 shares during the period. Quarry LP boosted its holdings in shares of Alphatec by 79.2% in the fourth quarter. Quarry LP now owns 5,374 shares of the medical technology company’s stock valued at $49,000 after buying an additional 2,375 shares during the period. Finally, Newton One Investments LLC acquired a new position in shares of Alphatec in the fourth quarter valued at approximately $50,000. Institutional investors and hedge funds own 66.35% of the company’s stock.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.